Descriptive exploration of overdose codes in hospital and emergency department discharge data to inform development of drug overdose morbidity surveillance indicator definitions in ICD-10-CM.


Journal

Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention
ISSN: 1475-5785
Titre abrégé: Inj Prev
Pays: England
ID NLM: 9510056

Informations de publication

Date de publication:
03 2021
Historique:
received: 28 02 2020
revised: 02 11 2020
accepted: 13 11 2020
entrez: 6 3 2021
pubmed: 7 3 2021
medline: 5 10 2021
Statut: ppublish

Résumé

In October 2015, discharge data coding in the USA shifted to the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM), necessitating new indicator definitions for drug overdose morbidity. Amid the drug overdose crisis, characterising discharge records that have ICD-10-CM drug overdose codes can inform the development of standardised drug overdose morbidity indicator definitions for epidemiological surveillance. Eight states submitted aggregated data involving hospital and emergency department (ED) discharge records with ICD-10-CM codes starting with T36-T50, for visits occurring from October 2015 to December 2016. Frequencies were calculated for (1) the position within the diagnosis billing fields where the drug overdose code occurred; (2) primary diagnosis code grouped by ICD-10-CM chapter; (3) encounter types; and (4) intents, underdosing and adverse effects. Among all records with a drug overdose code, the primary diagnosis field captured 70.6% of hospitalisations (median=69.5%, range=66.2%-76.8%) and 79.9% of ED visits (median=80.7%; range=69.8%-88.0%) on average across participating states. The most frequent primary diagnosis chapters included injury and mental disorder chapters. Among visits with codes for drug overdose initial encounters, subsequent encounters and sequelae, on average 94.6% of hospitalisation records (median=98.3%; range=68.8%-98.8%) and 95.5% of ED records (median=99.5%; range=79.2%-99.8%), represented initial encounters. Among records with drug overdose of any intent, adverse effect and underdosing codes, adverse effects comprised an average of 74.9% of hospitalisation records (median=76.3%; range=57.6%-81.1%) and 50.8% of ED records (median=48.9%; range=42.3%-66.8%), while unintentional intent comprised an average of 11.1% of hospitalisation records (median=11.0%; range=8.3%-14.5%) and 28.2% of ED records (median=25.6%; range=20.8%-40.7%). Results highlight considerations for adapting and standardising drug overdose indicator definitions in ICD-10-CM.

Sections du résumé

BACKGROUND
In October 2015, discharge data coding in the USA shifted to the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM), necessitating new indicator definitions for drug overdose morbidity. Amid the drug overdose crisis, characterising discharge records that have ICD-10-CM drug overdose codes can inform the development of standardised drug overdose morbidity indicator definitions for epidemiological surveillance.
METHODS
Eight states submitted aggregated data involving hospital and emergency department (ED) discharge records with ICD-10-CM codes starting with T36-T50, for visits occurring from October 2015 to December 2016. Frequencies were calculated for (1) the position within the diagnosis billing fields where the drug overdose code occurred; (2) primary diagnosis code grouped by ICD-10-CM chapter; (3) encounter types; and (4) intents, underdosing and adverse effects.
RESULTS
Among all records with a drug overdose code, the primary diagnosis field captured 70.6% of hospitalisations (median=69.5%, range=66.2%-76.8%) and 79.9% of ED visits (median=80.7%; range=69.8%-88.0%) on average across participating states. The most frequent primary diagnosis chapters included injury and mental disorder chapters. Among visits with codes for drug overdose initial encounters, subsequent encounters and sequelae, on average 94.6% of hospitalisation records (median=98.3%; range=68.8%-98.8%) and 95.5% of ED records (median=99.5%; range=79.2%-99.8%), represented initial encounters. Among records with drug overdose of any intent, adverse effect and underdosing codes, adverse effects comprised an average of 74.9% of hospitalisation records (median=76.3%; range=57.6%-81.1%) and 50.8% of ED records (median=48.9%; range=42.3%-66.8%), while unintentional intent comprised an average of 11.1% of hospitalisation records (median=11.0%; range=8.3%-14.5%) and 28.2% of ED records (median=25.6%; range=20.8%-40.7%).
CONCLUSION
Results highlight considerations for adapting and standardising drug overdose indicator definitions in ICD-10-CM.

Identifiants

pubmed: 33674330
pii: injuryprev-2019-043520
doi: 10.1136/injuryprev-2019-043520
pmc: PMC7948180
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

i27-i34

Subventions

Organisme : NCIPC CDC HHS
ID : U17 CE002719
Pays : United States
Organisme : NCIPC CDC HHS
ID : U17 CE002727
Pays : United States
Organisme : NCIPC CDC HHS
ID : U17 CE002731
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: LMTS, SN, PR, JWD and BAG report grant funding from the CDC during the conduct of this study. All other authors have nothing to disclose.

Références

MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427
pubmed: 30605448
Public Health Rep. 2020 Mar/Apr;135(2):262-269
pubmed: 32040923
MMWR Morb Mortal Wkly Rep. 2018 Mar 09;67(9):279-285
pubmed: 29518069
Inj Prev. 2021 Mar;27(S1):i56-i61
pubmed: 33674334
Med Care. 2017 Nov;55(11):918-923
pubmed: 28930890
Adv Wound Care (New Rochelle). 2013 Dec;2(10):588-592
pubmed: 24761333
Inj Epidemiol. 2018 Oct 1;5(1):36
pubmed: 30270412

Auteurs

Leigh M Tyndall Snow (LM)

Office of Public Health, Louisiana Department of Health, Baton Rouge, Louisiana, USA tyndallsnowl@gmail.com.

Katelyn E Hall (KE)

Colorado Department of Public Health and Environment, Denver, Colorado, USA.

Cody Custis (C)

Montana Department of Public Health and Human Services, Helena, Montana, USA.

Allison L Rosenthal (AL)

Colorado Department of Public Health and Environment, Denver, Colorado, USA.

Emilia Pasalic (E)

National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sarah Nechuta (S)

Tennessee Department of Health, Office of Informatics and Analytics, Nashville, TN, USA.

James W Davis (JW)

New Mexico Department of Health, Injury & Behavioral Epidemiology Bureau, Santa Fe, New Mexico, USA.

Bretta Jane Jacquemin (BJ)

New Jersey Department of Health, Center for Health Statistics and Informatics, Trenton, New Jersey, USA.

Sherani R Jagroep (SR)

North Carolina Department of Health and Human Services, Injury and Violence Prevention Branch, Raleigh, North Carolina, USA.

Peter Rock (P)

Kentucky Injury Prevention and Research Center, University of Kentucky, Lexington, Kentucky, USA.

Elyse Contreras (E)

Colorado Department of Public Health and Environment, Denver, Colorado, USA.

Barbara A Gabella (BA)

Colorado Department of Public Health and Environment, Denver, Colorado, USA.

Katherine A James (KA)

Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH